MCI PRO 315

Generali MCI Pro 315 is not a standalone policy — it is a multi-stage critical-illness rider that attaches to a Generali BeSMART or BeSMART Lite base policy. It pays out in stages along the trajectory of a critical illness, rather than once at terminal diagnosis. Early stage triggers an Early Stage Benefit (100% of Sum Assured) plus a quarterly Extra Early Stage Benefit (up to 40% across instalments). If the condition worsens to Late Stage, the rider pays another 100% of Sum Assured plus an Extra Late Stage Benefit (20%). On top of that, a Catastrophic Benefit (100%) covers events such as organ transplant, and a Diabetes Complication Benefit (100%) covers diabetic complications such as retinopathy.

Aggregated across the stages — and assuming the customer’s clinical path uses several of the trigger benefits over the policy life — the maximum cumulative payout is up to 315% of Sum Assured. That is the “315” in the product name. It is not 315 distinct conditions and it is not three independent stages of 105% each — it is the headline maximum aggregate across the multi-stage payout stack.

In one line: Critical illness rarely strikes once and stays still. MCI Pro 315 is built around the path the disease actually takes — early diagnosis, late-stage progression, and the costly downstream events — and pays at each step.

---

The official Generali brochure uses Pak Surya Putra, 30yo male, Rp 500M MCI Pro 315 Sum Assured, attached to BeSMART Lite Rp 200M base SA, 20-year premium payment term, total annual premium Rp 8.96M (of which Rp 7.47M is the MCI Pro 315 rider premium). Decoded for the agent narrative:

Critical insight for the agent narrative: the headline “315%” looks like a comprehensive cap, but in practice few customers will trigger every stage. The realistic clinical path is one of: (a) early-stage diagnosis with successful treatment → 100% + up to 40% paid, rider continues for late stage if disease later progresses; (b) direct late-stage diagnosis → 100% + 20% paid; © catastrophic event in isolation → 100%. Frame MCI Pro 315 not as “you’ll get 315%” but as the rider that pays at every milestone of the illness, however the disease unfolds. The 315% cap is the structural promise; the typical payout is one or two stages.

---

Sweet Spot — Lead with MCI Pro 315

• Age 32-55, married, 1-3 dependents, has at least one parent or sibling with a critical-illness history (cancer, stroke, diabetes complications, heart disease)
• Household income Rp 15M+/month — comfortable absorbing Rp 7-12M annual rider premium alongside base policy
• Already has medical card / HMO covering hospitalisation — this is the cash-on-diagnosis layer, not the reimbursement layer
• Already owns or is buying a BeSMART or BeSMART Lite base policy (rider cannot stand alone)
• Has visible exposure to a specific multi-stage disease: family history of cancer, diabetic parent, history of cardiovascular events in close family
• Comfortable with the idea of paying for a multi-stage rider where the highest payout requires the most severe outcome — does not need every rupiah of premium to come back in a “value for money” frame

Borderline Fit — Discuss but qualify

• Age 56-65 — entry is permitted up to age 65, but rider premium loads heavily and the relative benefit window is shorter; discuss whether the spend is better directed at a standalone term CI product or a comprehensive medical plan upgrade
• Customers with managed chronic conditions (hypertension, dyslipidemia, pre-diabetes) — likely face underwriting loading or exclusion; do not assume clean acceptance
• Customers who do not have BeSMART or BeSMART Lite yet — pair sale required; assess base-policy fit first, then layer the rider
• Single high-income earners with no dependents and no family history — possible if framing is “pre-fund my own catastrophic event so I do not become a burden”, but conversion needs the right anchor

Do Not Pitch

• Mass middle market who do not have basic medical insurance — refer them to BPJS Kelas 1 or a private HMO product first; CI on top of no hospital cover is the wrong sequencing
• Customers actively shopping a lump-sum CI product who want a single trigger and a single payout — MCI Pro 315 is structurally different; lead them to a comprehensive CI lump-sum (e.g., AIA Vital Care, Allianz Critical Plus advanced-only configuration)
• Investment-seeking customers — there is no investment component; MCI Pro 315 is pure risk transfer
• Late-life prospects 66+ — entry-age cap is 65 at nearest birthday
• Customers with budget headroom of Rp 3M/year or less — the rider plus base BeSMART Lite stack starts around Rp 8-9M annual for a 30yo at Rp 500M SA; under-funded buyers will lapse

---

Rule of thumb: if the customer’s first sentence contains “kanker turunan” (hereditary cancer), “diabetes di keluarga” (diabetes in family), “tahapan penyakit” (stages of disease), or “saya sudah ada BeSMART” (I already have BeSMART), MCI Pro 315 belongs in the conversation. If their first sentence is “saya cuma mau cover satu kali kalau kena penyakit kritis” (I just want a single CI payout) or “saya cari yang paling murah” (I am looking for the cheapest), a standalone lump-sum CI is the better lead and MCI Pro 315 is not the right product.

---

Drawn from ~28 agency CI products catalogued in the Indonesia Life Insurance Market Intelligence database across 11+ insurers (Allianz, AIA, Prudential, Generali, Manulife, Mandiri, CIMB Niaga, TMLI, Bank Mega entities, others). The critical-illness category is structurally heterogeneous: standalone lump-sum CI (term or whole-life), CI-with-waiver-only riders, comprehensive multi-stage CI, and condition-specific CI (cancer-only, heart-only). Quantitative benchmarking is limited (PDF coverage <60% on most metrics); the comparison below is descriptive and qualitative against the catalogued peer set.

---

Opening — establish the right frame

“Most critical-illness products treat the disease like a single event — you are diagnosed, the policy pays, the story ends. But a real cancer story, a real stroke story, a real diabetes story does not work like that. There is the diagnosis. There is the treatment. If things go badly, there is the late stage. And sometimes there is the catastrophic event — the transplant, the major surgery. MCI Pro 315 is built around that real path, not a single moment.”

“Kebanyakan produk penyakit kritis itu memperlakukan penyakit sebagai satu peristiwa — terdiagnosa, polis bayar, selesai. Tapi cerita kanker sungguhan, cerita stroke sungguhan, cerita diabetes sungguhan tidak jalan seperti itu. Ada momen diagnosa. Ada masa pengobatan. Kalau memburuk, ada tahap akhir. Dan kadang ada peristiwa katastropik — transplantasi, operasi besar. MCI Pro 315 dirancang sesuai jalur nyata itu, bukan satu titik saja.”

The structural value prop (the multi-stage payout stack)

“When MCI Pro 315 is in your protection plan, the policy pays at every important milestone of the illness. Early stage diagnosis triggers 100% of the cover plus an extra amount paid quarterly — that becomes your treatment cash. If the disease progresses to late stage, the policy pays another 100% plus an additional amount on top. If you need a transplant, that triggers a separate 100% payout. If diabetes complications strike, that is another 100%. Up to 315% of your cover across the journey. The product is built to keep paying as the disease unfolds, not to pay once and disappear.”

“Saat MCI Pro 315 masuk ke rencana proteksi Anda, polisnya bayar di setiap milestone penting dari penyakit. Diagnosa tahap awal langsung trigger 100% dari uang pertanggungan ditambah jumlah ekstra yang dibayar per tiga bulan — itu jadi uang tunai untuk pengobatan. Kalau penyakitnya berlanjut ke tahap akhir, polis bayar 100% lagi ditambah tambahan di atasnya. Kalau perlu transplantasi, ada 100% terpisah. Kalau ada komplikasi diabetes, itu lagi 100%. Sampai 315% dari uang pertanggungan sepanjang perjalanannya. Produknya dibuat untuk terus bayar selama penyakitnya berkembang, bukan bayar sekali lalu hilang.”

The pair-sell narrative (rider + base)

“MCI Pro 315 is not a standalone policy — it sits on top of your Generali base, BeSMART or BeSMART Lite. The base is your foundation; the rider is your critical-illness shield. That is intentional. The base policy handles the life-coverage piece. The rider handles the long, expensive, multi-stage journey of a critical illness. Together, the protection is layered the way a household actually needs it.”

“MCI Pro 315 bukan polis berdiri sendiri — dia naik di atas polis dasar Generali Anda, BeSMART atau BeSMART Lite. Dasarnya adalah fondasi; rider-nya adalah perisai penyakit kritis. Itu memang sengaja dirancang begitu. Polis dasar handle proteksi jiwa-nya. Rider handle perjalanan panjang, mahal, dan multi-tahap dari penyakit kritis. Berlapis sesuai kebutuhan keluarga sebenarnya.”

The diabetes anchor (when family history fits)

“Your father has diabetes. Your aunt has diabetes. Most CI products in this market exclude diabetes complications or treat them as a pre-existing risk. MCI Pro 315 is one of the few where a covered diabetes complication — retinopathy that cannot be reversed, late-stage kidney damage from diabetes, that kind of event — triggers a full 100% payout. That is specifically why I am recommending this product for someone with your family history.”

“Bapak diabetes. Tante diabetes. Kebanyakan produk CI di pasar ini exclude komplikasi diabetes atau menganggapnya pre-existing. MCI Pro 315 termasuk yang langka di mana komplikasi diabetes yang ditanggung — retinopati yang tidak bisa dipulihkan, kerusakan ginjal tahap akhir karena diabetes, kondisi seperti itu — trigger pembayaran penuh 100%. Itu sebabnya saya rekomendasikan produk ini khusus untuk orang dengan riwayat keluarga seperti Anda.”

—

Objection 1: “I already have health insurance. Why would I need this?”

Customer “I already have a hospital card, why do I need critical-illness cover on top of that?”

Customer “Saya sudah ada kartu rumah sakit, kenapa perlu cover penyakit kritis lagi?”

Don't say “Your medical card is not enough — you need this too.” — pressures the customer into a false either/or.

Don't say “Kartu rumah sakit Anda tidak cukup — Anda butuh ini juga.”

Do say “Your medical card pays the hospital — that part is covered. What it does not pay is the income you lose during six months of cancer treatment, the cost of out-of-network specialists, the home modifications after a stroke, or the unpaid leave when one of you stops working to care for the other. MCI Pro 315 is cash in hand on diagnosis. You decide where it goes. It is the bridge between hospital coverage and family reality.”

Do say “Kartu rumah sakit Anda bayar rumah sakitnya — itu sudah ter-cover. Yang tidak dibayar adalah penghasilan yang hilang selama enam bulan pengobatan kanker, biaya dokter spesialis di luar jaringan, modifikasi rumah setelah stroke, atau cuti tanpa gaji saat salah satu dari Anda berhenti kerja untuk merawat yang lain. MCI Pro 315 itu uang tunai langsung saat diagnosa. Anda yang tentukan dipakai untuk apa. Itu jembatan antara cover rumah sakit dengan kenyataan keluarga.”

—

Objection 2: “The premium is high for something I might never use.”

Customer “Rp 7-8 million a year for the rider feels expensive for an event that might never happen.”

Customer “Rp 7-8 juta setahun untuk rider-nya terasa mahal untuk kejadian yang mungkin tidak pernah terjadi.”

Don't say “It is cheap if you think about it.” — fights the customer’s frame.

Don't say “Murah kalau dipikir-pikir.”

Do say “Fair, let me reframe. The Indonesian Ministry of Health data shows roughly one in three adults will face a major critical illness before age 65. The premium for MCI Pro 315 at your age is about Rp 20,000 a day — less than parking at the mall. If you never claim, you have spent a daily parking fee on certainty. If you do claim, the rider pays out multiples of every premium you ever put in. The question is not the cost; it is whether you want the certainty available.”

Do say “Adil, mari kita bingkai ulang. Data Kemenkes menunjukkan kira-kira satu dari tiga orang dewasa akan menghadapi penyakit kritis besar sebelum usia 65. Premi MCI Pro 315 di usia Anda sekitar Rp 20 ribu per hari — kurang dari parkir di mall. Kalau tidak pernah klaim, Anda habiskan biaya parkir harian untuk kepastian. Kalau klaim, rider-nya bayar kelipatan dari setiap rupiah premi yang pernah Anda taruh. Pertanyaannya bukan biayanya; tapi apakah Anda mau punya kepastian itu.”

—

Objection 3: “If I do not claim, the money is wasted.”

Customer “Other CI products give my premium back if I do not claim. This one does not. So if I stay healthy, I lose everything.”

Customer “Produk CI lain ada yang kembalikan premi kalau saya tidak klaim. Ini tidak. Jadi kalau saya sehat, semua uangnya hilang.”

Don't say “You will probably claim.” — dark and not selling.

Don't say “Anda pasti akan klaim kok.”

Do say “True — MCI Pro 315 is a pure risk rider. No return-of-premium tail. Here is the trade-off in plain numbers. Products that refund all your premiums at the end charge you more upfront, and the refund schedule is calibrated so you are effectively pre-funding your own refund. MCI Pro 315 is priced for the protection only, not for the refund. That makes the per-rupiah-of-cover cost lower than ROP competitors. If a refund tail is non-negotiable for you, Allianz Critical Plus is the right product. If pure protection per rupiah is what you want, MCI Pro 315 wins on math.”

Do say “Benar — MCI Pro 315 itu rider proteksi murni. Tidak ada pengembalian premi di akhir. Trade-off-nya dalam angka jelas: produk yang refund semua premi di akhir charge lebih tinggi di depan, dan skema refund-nya disetel supaya Anda effectively pre-fund refund Anda sendiri. MCI Pro 315 dihargai untuk proteksinya saja, bukan untuk refund. Itu yang bikin biaya per rupiah cover lebih rendah dibanding kompetitor yang ada refund. Kalau refund tail itu wajib buat Anda, Allianz Critical Plus produk yang tepat. Kalau proteksi murni per rupiah yang Anda mau, MCI Pro 315 menang di matematika.”

—

Objection 4: “What if my condition is not on the list?”

Customer “Every CI policy has a long list, but my specific illness might not be on it. How do I know I am actually covered?”

Customer “Setiap polis CI punya daftar panjang, tapi penyakit spesifik saya mungkin tidak ada di situ. Bagaimana saya tahu benar-benar ter-cover?”

Don't say “Don’t worry, it is on the list.” — false reassurance that can come back.

Don't say “Tenang, pasti masuk daftar kok.”

Do say “Right question. MCI Pro 315 organises covered conditions by organ system, not by condition name alone — cardiovascular, liver, kidney, respiratory, digestive, sensory, neurologic, neuromuscular — and then names the five most common CIs explicitly: cancer, stroke, heart attack, terminal illness, and diabetes complications. The trade-off: if your specific condition does not fall under one of those organ systems and is not one of the five named CIs, it will not pay. Before you sign, I will walk through the RIPLAY definitions with you against your family history specifically. If there is a known family condition that does not fit, we will talk through it before SPAJ. No surprises later.”

Do say “Pertanyaan yang tepat. MCI Pro 315 mengelompokkan kondisi yang ditanggung berdasarkan sistem organ, bukan sekadar nama penyakit — kardiovaskular, hati, ginjal, pernapasan, pencernaan, sensorik, syaraf, neuromuskular — lalu menyebut lima CI paling umum secara eksplisit: kanker, stroke, serangan jantung, terminal illness, dan komplikasi diabetes. Trade-off-nya: kalau kondisi spesifik Anda tidak masuk salah satu sistem organ itu dan tidak termasuk lima CI yang disebut, tidak akan dibayar. Sebelum Anda tanda tangan, saya akan jalanin definisi RIPLAY-nya bersama Anda berdasarkan riwayat keluarga Anda. Kalau ada kondisi keluarga yang tidak cocok, kita bicarakan dulu sebelum SPAJ. Tidak ada kejutan di belakang.”

—

Objection 5: “BPJS or my company medical can cover this.”

Customer “I have BPJS and my company gives me a medical plan. Why do I need this?”

Customer “Saya sudah ada BPJS dan kantor saya kasih medical plan. Buat apa ini lagi?”

Don't say “BPJS does not cover critical illness.” — partially false; BPJS does cover treatment costs for many CI conditions.

Don't say “BPJS tidak cover penyakit kritis.”

Do say “BPJS pays for hospital treatment — and yes, BPJS will cover a lot of your cancer chemotherapy or your stroke rehabilitation through the BPJS-approved hospitals. That is real. What BPJS does not pay is the cash you need during the months you cannot work, the costs your family takes on, the loss of income for a household partner who quits to care for you. Company medical plans end the moment you leave the company — and a serious diagnosis usually means leaving the company. MCI Pro 315 is yours, follows you, and pays cash directly to you on diagnosis. It complements BPJS and company cover; it does not replace them.”

Do say “BPJS bayar pengobatan rumah sakit — dan ya, BPJS cover banyak kemoterapi kanker atau rehab stroke Anda di rumah sakit yang ter-jaminan. Itu nyata. Yang tidak dibayar BPJS adalah uang tunai yang Anda butuhkan selama berbulan-bulan tidak bisa kerja, biaya yang ditanggung keluarga, hilangnya penghasilan dari pasangan rumah tangga yang berhenti kerja untuk merawat Anda. Medical plan kantor itu berhenti saat Anda keluar dari kantor — dan diagnosa serius biasanya berarti keluar dari kantor. MCI Pro 315 milik Anda, ikut Anda, dan bayar tunai langsung ke Anda saat diagnosa. Dia melengkapi BPJS dan cover kantor; bukan menggantikan.”

—

1. Definition-driven payout — the “315%” headline must come with the qualifier. OJK conduct-of-business rules under POJK 23/2025 require that headline figures be accompanied by the conditions that trigger them. “Up to 315% of Sum Assured” is structurally accurate but never typical. Always explain in writing: 315% is the cumulative maximum across all stages over the policy life; the realistic claim path is one or two stages and lands well below 315%. Failing this disclosure is a top mis-selling vector.

2. Stage definitions must be walked through, not summarised. “Early stage cancer” in MCI Pro 315 is defined by the RIPLAY against specific histological / staging criteria. A customer who hears “any cancer diagnosis pays out” will be disappointed when an in-situ lesion does not meet the staging threshold. Walk through the early-stage definition with the customer at SPAJ and document the conversation.

3. The 90-day waiting period is non-negotiable. No claim payable for any CI diagnosed (or whose symptoms manifested) within 90 calendar days of policy issue, last reinstatement, or last benefit-altering modification. Customers with a current undiagnosed symptom — a recently noticed lump, a pending biopsy, ongoing chest pain — must complete the waiting period before MCI Pro 315 protection kicks in. Selling to a customer with active symptoms is a future repudiation risk.

4. Pre-existing condition exclusion is broad and triggers automatically. Conditions that existed at policy issue, whether disclosed or not, are excluded unless Generali explicitly accepts them. The customer carries the disclosure burden — undisclosed managed hypertension, dyslipidemia, fatty liver, or diabetes that later leads to a CI claim can void the claim. Be aggressive about asking, document the answers on the SPAJ, and counter-sign.

5. Rider-only structure must be disclosed upfront. MCI Pro 315 cannot stand alone — if the base BeSMART or BeSMART Lite policy lapses, surrenders, or terminates, the rider terminates as well. Customers who expect “their CI cover to keep running even if I cancel the life policy” are misinformed. Make this dependency explicit at SPAJ and on the policy schedule.

6. CI premium waiver is not built in to the rider. If the customer wants their premiums to stop when CI hits, a separate Waiver of Premium rider must be added to the base BeSMART policy. The brochure illustration shows WOP attached. Sell the WOP alongside MCI Pro 315 by default — pitching the rider in isolation and leaving WOP off is a structural mis-sell of the customer’s outcome expectation.

7. The list of catastrophic and diabetes-complication conditions is finite. “Catastrophic Benefit” covers events meeting RIPLAY definitions (major organ transplant being the prototype); not every “catastrophe” the customer imagines will qualify. Similarly “Diabetes Complication” covers RIPLAY-listed complications. Showing the customer the policy-defined event list, in writing, at SPAJ stage is the cleanest compliance posture.

---

---

1. Build a side-by-side “MCI Pro 315 vs Allianz Critical Plus” agent reference one-pager. Critical Plus is the comparable benchmark within Legacy Income’s catalog: 3-tier vs multi-stage, term standalone vs rider, ROP tail vs no tail, ~125% effective payout cap vs 315% cap. Quantify the trade-off in plain numbers for a 35yo at Rp 500M cover. Agents will be asked this comparison constantly in the field. Distribute by 2026-06-15.

2. Run a “315 decoded” objection-handling drill for the Star Network agency partners selling Generali. The “315%” headline will be questioned by every prospect who reads the brochure carefully. Train every agent to articulate: (a) what 315 actually means, (b) the realistic claim path, © the typical cumulative payout. A 30-minute Zoom drill plus a recorded reference will reduce the mis-selling complaint surface.

3. Pair-sell training: WOP rider must be sold alongside MCI Pro 315 by default. Without WOP on the base policy, a customer who triggers an Early-Stage Benefit still has to keep paying premiums on the base BeSMART. Most prospects intuitively expect their premium to stop when CI hits. Make WOP a standard part of the SPAJ template for MCI Pro 315 customers — agents should have to consciously deselect WOP rather than consciously add it.

4. Survival-period and definition-walk-through must be on the SPAJ checklist. Every MCI Pro 315 SPAJ should include a customer-counter-signed page confirming the customer understands: (a) the 90-day waiting period, (b) the stage-definition concept, © the pre-existing condition exclusion, (d) the rider-on-base dependency. Build the checklist by 2026-06-01 and require sign-off on every case from 2026-06-15.

5. Family-history conversation script for the diabetes anchor. The Diabetes Complication Benefit is one of MCI Pro 315’s strongest differentiators in the Indonesian market. Write a script that opens with “Tell me about diabetes in your family” and routes the conversation toward MCI Pro 315 for prospects with a clear family history. Test in 10 live pitches; iterate. This is the single highest-leverage selling angle for the product.

---